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confirmed allergic events in the iron dextran-tolerant group.Sodium ferric gluconate complex in hemodialysis patients. II.
Long-term exposure to SFGC in iron dextran-sensitive patientsAdverse reactions in iron dextran-sensitive and dextran-toler-
resulted in intolerance in only one additional patient and noant patients.
serious adverse events.Background. Iron dextran administration is associated with
Conclusions. Patients with a history of iron dextran sensitiv-a high incidence of adverse reactions including anaphylaxis and
death. Although dextran, rather than iron, is believed to be the ity had approximately sevenfold higher rates of reaction to
cause of these reactions, it is not known whether iron dextran- both placebo and SFGC compared to iron dextran tolerant
sensitive patients can be safely administered another form of patients. However, logistic regression analysis, performed to
parenteral iron, sodium ferric gluconate in sucrose (SFGC). account for the higher reaction rate to placebo, suggests that
Methods. In a 69 center, prospective, double-blind, con- this increased reactivity was not drug-specific nor immunologi-
trolled trial of safety and tolerability of SFGC, the rate of cally mediated, but represented host idiosyncrasy. These results
reactions to SFGC and placebo in 144 iron dextran-sensitive support the conclusions that reactions to SFGC can be attrib-
patients was compared with 2194 patients who were previously uted to pseudoallergy, and that SFGC is not a true allergen.
tolerant to iron dextran preparations. Serum tryptase levels, a
marker of mast cell degranulation, also were measured.
Results. Among 143 iron dextran-sensitive patients exposed
to SFGC, three (2.1%) were intolerant. All three had suspected The frequent blood loss associated with dialysis and
allergic events to SFGC, including one patient with a serious its related procedures is estimated to result in 1 to 3 grams
reaction (0.7%). One dextran-sensitive patient (0.7%) had a of iron loss per year in chronic hemodialysis patients [1].suspected allergic reaction after placebo. In contrast, among
Regular administration of iron to hemodialysis patients2194 iron dextran-tolerant patients, reactions to SFGC were
significantly less common, with SFGC intolerance seen in seven increases the percentage of patients in the target hemo-
patients (0.3%; P  0.020), including five (0.2%) who had globin range and reduces requirements for recombinant
suspected allergic events (P 0.010), but none who had serious human erythropoietin (epoetin). Guidelines from both
events (0.0%; P  0.061). Two iron dextran-tolerant patients
American and European nephrology groups recommend(0.09%) had allergic-like reactions following placebo injec-
administration of intravenous iron as both repletion andtions. Two of the three suspected allergic events in the iron
dextran-sensitive group were confirmed as mast cell dependent maintenance therapy in hemodialysis patients [2, 3] to
by a 100% increase in serum tryptase, while there were no achieve target hemoglobin and ensure efficient use of
erythropoietin.
For many years the only form of parenteral iron avail-Key words: allergy, drug safety, intravenous iron, renal failure, tryp-
tase, anemia, parenteral iron, hemoglobin. able in the United States was iron dextran. Review of
drug reporting databases by Faich and Strobos identified
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per million doses per year with sodium ferric gluconate based on information in the patient record and patient
complex in sucrose (SFGC) [4]. In the same study there history. A predefined secondary end-point of the blinded
were 74 “allergic” events related to SFGC administration. study was to evaluate the cross sensitivity of SFGC and
None of these 74 events associated with SFGC were fatal. iron dextran by comparing patients who previously toler-
In contrast, 31 of 196 (15.8%) of the allergic events ated iron dextran with those patients with prior iron
reported for iron dextran resulted in death. While pseudo- dextran intolerance. The federal Food and Drug Admin-
allergic reactions usually occur during the first exposure istration (FDA) approved the final study design.
to iron dextran, anaphylactic reactions can follow multi-
Patient selectionple uneventful exposures [5]. Furthermore, iron dextran
intolerance (which includes all forms of reactions) is Patients were enrolled in the double blind study at 69
common, occurring in approximately 2.5% of iron dex- centers in the U.S. between August 1999 and October
tran-naı¨ve patients [4]. The molecular weight of iron 2000, and all centers obtained approval from their re-
dextran also appears to influence the incidence of ana- spective Institutional Review Boards. Patient eligibility
phylactic and intolerance reactions, with higher molecu- and exclusion criteria have been reported in detail pre-
lar weight Dexferrum being associated with a higher viously [7]. Briefly, patients with known sensitivity to
incidence of reactions than InFeD [5]. These data have iron dextran were limited in this trial to avoid over-
called into question the wisdom of using iron dextran enrollment of atopic or multiple drug allergy patients,
preparations at all, particularly if safer parenteral iron which could bias the overall study toward over-reactions.
preparations are available [6]. Centers could enroll up to 10% of patients with a history
It is not known whether other forms of parenteral iron of iron dextran intolerance. Patients were excluded from
such as SFGC can be used safely in iron dextran-sensitive the study if they had prior treatment with SFGC, or were
patients. We have recently reported on a randomized undergoing acute or chronic therapy with antihistamines
double blind study of SFGC versus placebo in chronic or corticosteroids, which could mask possible allergic
dialysis patients in the United States that confirmed the reactions. The first 1412 patients completing the double-
safety of SFGC in a large number of patients, the vast blinded study without drug intolerance to SFGC then
majority of whom had prior iron dextran tolerance [7]. entered an open-label study of SFGC, described below.
Since SFGC does not contain any dextran moieties that
are thought to be important antigenic determinants, we Study design
hypothesized that the incidence of drug intolerance and Patients who satisfied the inclusion criteria and signed
adverse reactions to SFGC in those patients who did informed consent participated in the double-blind cross-
have a history of iron dextran-sensitivity would not ex- over study that included four sequential hemodialysis
ceed that seen with placebo administration. sessions (HD). The first session consisted of screening
We report here the results of SFGC and placebo ad-
procedures, medical history, review of medications and
ministration to the 144 patients from the randomized
allergy history, and physical exam. At the second session,
double blind study who had a history of prior iron dex-
patients were randomized into one of two crossover
tran reactions, as well as the results of subsequent admin-
treatment schedules: SFGC at HD session number 2 and
istration of multiple doses of SFGC to a subset of 92 iron
placebo at HD session number 3; or placebo at HD sessiondextran-sensitive patients who entered an open-label
number 2 and SFGC at HD session number 3. At HDstudy of SFGC. We also determined whether suspected
session number 4, the patient was assessed for any ad-allergic reactions following SFGC and placebo were mast
verse reactions after the third session. A single undilutedcell dependent by measuring serum tryptase, a marker
dose of 125 mg of SFGC was administered intravenouslyof mast cell degranulation.
over 10 minutes during the first hour of HD session
number 2 or 3. Placebo was composed of 10 mL of
METHODS bacteriostatic saline (containing 9 mg/mL of benzyl alco-
hol) and was administered at the same rate as SFGC atData were collected for patients with a history of iron
the other HD session. The placebo as well as study drugdextran allergies, known iron dextran tolerance, or sus-
contained the preservative benzyl alcohol so that anypected allergic reactions to SFGC during a multicenter,
reaction occurring after the study drug would be attribut-crossover, randomized, double-blind, placebo controlled
able only to SFGC. Unblinded personnel prepared bothprospective trial of SFGC performed in 2534 hemodialy-
placebo and SFGC; each syringe was covered with ansis patients [7]. Data also were collected from a subse-
adhesive opaque paper and attached to a needle with aquent open label long-term study of SFGC in 1412 pa-
steel hub to ensure blinding of personnel who adminis-tients successfully completing the double-blind study.
tered the drug and who reported any adverse events.Prior dextran sensitivities were classified by each partici-
pating center as mild, drug intolerance, or anaphylactoid, Vital signs (blood pressure and pulse) were recorded at
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Table 1. Patient demographic data tryptase [8–10] levels determined during HD session
number 2. By measuring tryptase levels, we defined theIron dextran Iron dextran
sensitive tolerant normal range for hemodialysis patients, which is not
Characteristics N  144 N  2194 different from the normal population (10 ng/mL).
Mean age 53.2 55.8 These results were used to define a significant increase
% Male 45.1a 55.3
in post-event tryptase level compared to the baseline pre-Ethnicity N (%)
White 23 (16.0) 474 (21.6) event tryptase level, being set at 2 standard deviations
Black 87 (60.4) 1297 (59.2) from the mean, which was a doubling of the pre-dialysis
Hispanic 26 (18.1) 363 (16.5)
value. All patients in the double-blind study had bloodOther 8 (5.5) 60 (2.7)
2 non-iron drug allergies 28 (19.4)b 294 (13.4) samples obtained prior to HD sessions number 2 and 3
for possible baseline tryptase levels. If a suspected imme-aP  0.02 compared to iron dextran tolerant group
bP  0.12 compared to iron dextran tolerant group diate-type allergic reaction occurred, a second tryptase
level was drawn approximately one hour after the event
to evaluate possible drug-induced mast cell degranula-
tion [8, 9]. If no reaction occurred, the baseline samplebaseline, five minutes into the injection, and at five and
was discarded.20 minutes after completion of the infusion [7].
The open label study began immediately following Statistical methods
successful completion of the double-blind crossover study.
Suspected and confirmed immediate-type allergicEach patient entering the open label study was assigned
events were compared between SFGC and placebo using20 vials each containing 62.5 mg of SFGC. The investiga-
McNemar’s Test, which discounts patients with reactionstor and the primary attending nephrologist had full dis-
to both drug and placebo. Logistic regression analysescretion on how to administer SFGC during the open
were performed on the incidence of all adverse eventslabel study. The patient completed the open label phase
to assess whether any cross-reactivity to iron dextranwhen all 1250 mg of SFGC had been administered or
was independently related to either SFGC or placebo.nine months had passed.
Statistical significance was assessed between iron dextran
exposed groups, with regards to the incidence of reac-Adverse events and allergic events
tions, by use of a two-sided Fisher’s Exact test. Statistical
Any adverse reaction that occurred during study drug
significance was assessed between iron dextran intolerant
infusion was classified as an instantaneous reaction; one
and iron dextran tolerant groups by using a two-sided
that occurred during the remainder of the dialysis session
Fisher’s Exact test.
was considered an immediate reaction. Before the initia-
tion of dialysis at the subsequent session, patients were
RESULTSreassessed for any intervening adverse events, which were
considered delayed reactions. Predefined adverse out- Among the 2534 patients enrolled in the double-blind
comes were classified by blinded personnel as: placebo-controlled trial, 2338 had previously received
iron dextran: 144 had prior iron dextran sensitivity and
(1) Drug intolerance events, which precluded further 2194 were known to be iron dextran-tolerant. The demo-
drug administration; graphics of these two groups are shown in Table 1. Iron
(2) Serious adverse events, which were any instanta- dextran-sensitive patients were less likely to be male (P
neous or immediate reactions requiring extraordi- 0.02). Multiple drug allergies were more common in the
nary treatment such as antihistamines, vasopres- iron dextran-sensitive group (P  0.12), although the
sors, or steroids; difference was not statistically significant.
(3) Suspected allergic events, which were any clinical Among the 144 patients with known iron dextran sen-
events suggesting drug allergy, such as pruritic sitivity, 143 were exposed to SFGC during the placebo-
rash, bronchospasm, or unexplained hypotension; controlled study. One patient had a reaction after pla-
and cebo and withdrew consent before receiving SFGC. The
(4) Confirmed immediate-type allergic events, which previous reactions to iron dextran preparations were
were any suspected allergic reaction accompanied classified as mild, drug intolerance, or anaphylactoid.
by a 100% increase in baseline serum tryptase level. The distributions of reactions by severity and iron dex-
tran preparations used at the time of the reaction are
Serum tryptase determinations shown in Table 2. Among the 2338 patients exposed to
The initial 206 hemodialysis patients receiving SFGC any form of iron dextran, 1937 (82.8%) had received
or placebo without incident at early selected sites had InFeD only, 261 (11.2%) had received Dexferrum
only, and 140 (6.0%) had received both drugs. The inci-baseline (immediate pre-dialysis) and post-dialysis total
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Table 2. Summary of reactions in iron dextran sensitive patients a prior history of anaphylactoid reactions to both com-
mercially available iron dextrans and allergic reactionsInFeD Dexferrum Total
to penicillin and cephalexin. The patient developed dys-Number exposed 2077 401 2338a
Any sensitivity 113 (5.4%)c 39 (9.7%)d 144 (6.2%)b pnea, hypotension, and wheezing which began four min-
Type of sensitivity utes after completion of the SFGC injection. The patient
Mild 24 (1.2%) 11 (2.7%) 32 (1.4%)b
was given intravenous diphenhydramine, intravenousDrug intolerance 60 (2.9%) 21 (5.2%) 77 (3.3%)b
Anaphylactoid 28 (1.3%) 7 (1.7%) 34 (1.5%)b hydrocortisone, and subcutaneous epinephrine. The re-
action resolved after 20 minutes, and the patient com-aSome patients were exposed to both agents, but are counted only once here
bSome patients were sensitive to both agents, but are counted only once here pleted the dialysis treatment and went home. The pa-
cOne patient was dextran sensitive, but the type of sensitivity was not classified
tient’s baseline serum tryptase level of 11.7 ng/mL wasdP  0.002 compared to InFed incidence
approximately twofold higher than average of the con-
trol group, consistent with constitutive, on-going mast
cell degranulation. Tryptase decreased after the reaction
dence of Dexferrum reactions was significantly higher to 10.8 ng/mL, and this serious adverse reaction was
(39/401; 9.7%) than reactions to InFeD (113/2077; 5.4%; therefore classified as a non-allergic event.
P  0.002). Among patients exposed to only one form Among the seven iron dextran-tolerant patients classi-
of iron dextran, Dexferrum reactions were still signifi- fied as intolerant to SFGC, two had reactions that were
cantly higher (24/261; 9.2%) than reactions to InFeD not consistent with an allergic event: isolated hypoten-
(105/1937; 5.4%) (P  0.021). sion (N 1), and nausea (1). Four of these iron dextran-
Tryptase levels were obtained predialysis and one tolerant patients had suspected allergic reactions to
hour after study drug administration in the first 206 pa- SFGC. These reactions were pruritus (2), chills (1), and
tients at selected sites during HD session number 2 of dyspnea with chest pain (1). One of these patients also
the double-blind trial. In this control group, baseline and experienced a delayed rash following placebo (discussed
post-dialysis tryptase levels were 4.45  3.44 and 4.62  later in this section). Tryptase did not increase more
4.06 ng/mL, respectively. These results demonstrated than 100% following any of these events, and therefore
that a tryptase value was detectable predialysis, was not all were classified as non-allergic events. The seventh
stimulated by dialysis, and was not significantly different patient had a delayed rash following SFGC; because a
than values in normal subjects [8]. A significant change post-event tryptase level could not be obtained this was
in tryptase levels was defined by these results as at least classified as an unconfirmed suspected allergic event.
a 100% increase compared to the baseline level. SFGC intolerance due to suspected allergic events was
significantly more common (P  0.010) in iron dextran-
Intolerance reactions to SFGC sensitive patients (3/143; 2.1%) than iron dextran-toler-
Three of the 143 patients (2.1%) with prior reactions ant patients (5/2194; 0.2%).
to iron dextran were considered intolerant to SFGC, while
Non-intolerance suspected allergic reactions to SFGCjust seven of 2194 (0.3%) iron dextran-tolerant patients
were considered intolerant to SFGC (P  0.020). One Six other patients, and the patient described earlier
patient was considered intolerant to placebo and was iron with a delayed rash following placebo, had suspected
dextran tolerant. Results are summarized in Table 3. Over- allergic events that were not considered severe enough to
all, patients with suspected allergic reactions did not have be classified as drug intolerance by the local investigator.
a significant increase in tryptase level (baseline 6.13  One of these patients had prior iron dextran sensitivity.
3.76 ng/mL; post-treatment 6.95  3.43 ng/mL), and Three of these reactions occurred after placebo: nausea,
these values were not significantly different than the dizziness, headache and vomiting in the patient with
control group’s baseline (4.45  3.44 ng/mL, P  0.118) prior iron dextran sensitivity (1); flushing and malaise
and post-treatment tryptase levels (4.62  4.06 ng/mL, (1); and a delayed rash (1). The four reactions following
P  0.063). SFGC were also possibly allergic, but were not consid-
Among the three intolerance reactions to SFGC in ered severe enough to warrant drug cessation. These reac-
the dextran-sensitive patients that precluded further ad- tions were: nausea, unease and dry throat (1); nausea and
ministration of SFGC, one patient had back pain follow- dizziness (1); rash (1); and pruritus (1). None of these
ing SFGC that was classified as mild by the local investi- reactions had 100% increase in tryptase post-event,
gator. Tryptase levels rose from 3.8 to 7.8 ng/mL; by and therefore they were not classified as confirmed aller-
definition a confirmed allergic reaction. A second patient gic events. Tryptase change from baseline could not be
developed instantaneous facial flushing on exposure to obtained in the delayed reaction.
SFGC. Tryptase increased from 2.1 to 4.9 ng/mL and A total of 15 patients of 2338 with prior dextran expo-
this response also was classified as a confirmed allergic sure had suspected allergic events during the double-
blind trial (Table 4). Twelve events occurred after SFGC,reaction. The third patient with SFGC intolerance had
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Table 3. Summary of SFGC intolerance by patient group
Iron dextran sensitive Iron dextran tolerant Total patients P valueb
End point N  143 N  2194 N  2338 (Fisher’s Exact Test)
SFGC intolerance 3 (2.1%) 7 (0.3%) 10 (0.4%) 0.020
Serious event 1 (0.7%) 0 (0.0%) 1 (0.04%) 0.061
Suspected allergic events 3 (2.1%)a 5 (0.2%) 8 (0.3%) 0.010
aIncludes serious event
bIron dextran-sensitive group compared to Iron dextran-tolerant group
Table 4. All suspected allergic events by patient group
Iron dextran sensitive Iron dextran tolerant Total patients
End point N  143 N  2194 N  2338
All suspected allergic events after SFGC 3 (2.1%)a 9 (0.4%)b 12 (0.5%)b
Delayedc 0 (0.0%) 1 (0.04%) 1 (0.04%)
Immediate 3 (2.1%) 8 (0.3%) 11 (0.5%)
Confirmed allergic event (tryptase increase 100%) 2 (1.4%) 0 (0.0%) 2 (0.08%)
Suspected allergic events after placebo 1 (0.7%) 2 (0.09%) 3 (0.12%)
a P  0.033 compared to iron dextran tolerant group
b Not all suspected allergic events were considered severe enough to warrant drug cessation. Four patients had mild immediate reactions not considered drug
intolerance. One patient had a suspected allergic reaction to both placebo and SFGC.
c Delayed reactions were reported after the end of dialysis and immediate reactions were reported during the dialysis session
and four events after placebo, an event rate that is not SFGC-intolerant. Eight iron dextran-sensitive patients
significantly different (P  0.12). One patient had sus- received at least one dose of SFGC of greater than 125
pected allergic events after both SFGC and placebo. Sus- mg during at least one treatment, and these eight each
pected allergic events following SFGC were significantly received an average cumulative dose of 1141 mg. None
more common (P  0.033) in iron dextran-sensitive pa- had a serious event, a suspected allergic event, nor were
tients (3/143; 2.1%) than iron dextran-tolerant patients considered intolerant to this higher dose of SFGC.
(9/2194; 0.4%). Similarly, suspected allergic events after Among the eight patients who had suspected allergic
placebo were more common in iron dextran-sensitive pa- reactions to SFGC or placebo during the double-blind
tients (1/143; 0.7%) than dextran-tolerant patients (2/2194; trial yet were not considered SFGC-intolerant, three en-
0.09%), but this was not statistically significant. tered the open label study, and received multiple doses
Among all 2534 patients enrolled in the study, only of SFGC. None had a serious event, however, one patient
two confirmed allergic reactions occurred; both were in complained of shortness of breath and a hot flash around
iron dextran-sensitive patients following SFGC. Logistic his neck two days after receiving his third dose of SFGC.
regression failed to identify cross-sensitivity between The investigator considered this reaction likely to be
SFGC and prior iron dextran sensitivity in the incidence drug related and discontinued the patient from the study.
of all adverse events (P  0.69). The low occurrence of
suspected allergic events did not permit direct logistic
DISCUSSIONregression analysis for these events.
Administration of parenteral iron is essential to achieve
Repeated exposure to SFGC and maintain target hemoglobin in hemodialysis patients.
Numerous studies have demonstrated that parenteralAmong the 2490 patients completing the double-blind
iron can increase hemoglobin in epoetin-treated dialysistrial with demonstrated tolerance to SFGC, 1412 entered
patients, and/or reduce the amount of epoetin neededan open label trial where 1250 mg of SFGC was adminis-
to achieve target hemoglobin. Practice guidelines fromtered within nine months in any fashion at the local
the National Kidney Foundation and the European Bestinvestigators’ discretion. Of the 140 iron dextran-sensi-
Practices Guidelines recommend repletion of iron storestive patients who were SFGC-tolerant, 92 entered this
in iron deficient hemodialysis patients, then maintenanceopen label trial. SFGC was administered as 125 mg
of those stores by regular administration of parenteralper treatment in 84 of these patients. Each of these
iron [2, 3].patients received an average cumulative dose of 1155 
In the United States, iron dextrans were the only ap-255 mg of SFGC. None had a serious event. One patient
proved forms of parenteral iron available until 1998.received five doses of SFGC uneventfully, complained
of mild pruritus with the sixth dose, and was then labeled Retrospective and prospective studies have established
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that iron dextrans can cause serious and life-threatening was not allergenic, based on the evidence that dextran,
and not iron oxide, accounts for these serious and life-hypersensitivity reactions [4]. A meta-analysis of studies
of intravenous iron dextran preparations found a drug threatening hypersensitivity reactions. In this context it
is important to note that drug reactions may result fromintolerance rate of 2.47  0.31%, and life threatening
reaction rate of 0.61 0.13% [7]. While all current intra- drug-specific immunological activity, or from “pseudo-
allergy” [21]. Pseudoallergy results in reactions consis-venous iron products contain iron oxide, there are sig-
nificant chemical variations in the iron ligands. Iron dex- tent with drug allergy, but is due to host idiosyncrasy
rather than a drug-specific immune response. There istran is composed of iron oxide crystals surrounded by a
matrix of cross-linked dextrans. Interestingly, our data no clear-cut method to distinguish drug immunoreactiv-
ity and pseudoallergy short of detection of drug-specificfound a significantly higher prevalence of intolerance to
Dexferrum (9.7%) than to InFeD (5.4%). Even among immunoglobulins [22]. Various forms of pseudoallergy
exist. Atopy increases risk of pseudoallergic events suchpatients exposed to only one brand of iron dextran, the
reaction rate was significantly higher following Dexfer- as radiocontrast reactions [23], probably due to fragile
or unstable mast cells with increased “releaseability” onrum. These results are consistent with a previous report
and the suggestion that Dexferrum iron dextran may exposure to various stimuli [24]. Multiple drug allergy
patients often have increased sensitivity to many chemi-be more allergenic than InFeD [5].
In contrast to iron dextran, SFGC has a single ligand cally dissimilar drugs [25, 26]. Finally, some individuals
have repeated reactions (including to placebo) presum-for each of the five available iron oxide coordinating
positions—one gluconate and four sucrose molecules— ably based on classically conditioned learned behavior
[27]. We hypothesized that reactions following SFGCresulting in an iron oxide polymer rather than iron oxide
crystals. Additionally, SFGC contains no dextrans, which would reflect pseudoallergy and be characterized by a
low incidence similar to placebo, insignificant mast cellmay well account for its favorable adverse effect profile
compared to iron dextran preparations. activation, and would segregate to patients with histories
of other drug allergies.In this study, SFGC was remarkably well tolerated,
with 140 of 143 iron dextran-sensitive patients receiving We first assessed whether SFGC is allergenic by blinded,
subjective identification of suspected allergic reactionsSFGC without incident. Ninety-two of these patients en-
tered the open label trial and 91 received repeated doses based on a temporal relationship to drug administration.
Among all patients, suspected allergic reactions follow-of SFGC without incident. Nevertheless, the incidence of
intolerance reactions to SFGC among the dextran-sensi- ing SFGC were low in incidence (0.5%) and not statisti-
cally different from the rate following placebo (0.2%).tive patients was approximately sevenfold higher than
observed in the dextran-tolerant population (2.1 vs. These data both support the hypothesis and confirm the
value of the placebo control study design.0.3%, P  0.020). Similarly, the incidence of suspected
allergic reactions in the dextran-sensitive group was ap- Secondly, SFGC allergenicity was assessed by de-
termining pre- and post-reaction serum mast cell-derivedproximately fivefold higher than observed in the dextran-
tolerant patients (2.1 vs. 0.4%, P  0.010). The iron tryptase levels in patients with immediate-type suspected
allergic reactions. Tryptase, a marker of mast cell activa-dextran-sensitive patients also had a sevenfold higher
reaction rate following placebo administration (0.7 vs. tion, has not been used heretofore to assess drug aller-
genicity in large scale studies. It appears that clinically-0.09%), suggesting that these patients may be predis-
posed to drug reactions. significant drug reactions are accompanied by at least a
100%-rise in baseline serum tryptase levels [9, 28]. TheAlthough the proportion of iron dextran-intolerant
patients who were intolerant or experienced sensitivity appropriateness of this cut-off was confirmed by mea-
surement of baseline and post-dialysis levels in 206 he-reactions with SFGC was statistically higher than iron
dextran-tolerant patients, the results of our study show modialysis patients as part of this study. Both patients
with significant mast cell degranulation following admin-that SFGC can be used safely in the vast majority of
these patients even if they have a prior history of iron istration of SFGC had a prior history of iron dextran
sensitivity. These reactions (back pain, and facial flush-dextran intolerance. It is important to note that while
hypersensitivity reactions following SFGC have been re- ing) could have resulted from pseudoallergy based on
the history of prior drug sensitivity, the lack of cross-ported anecdotally, serious reactions are extremely rare
and there have been no published reports of fatal reac- reactivity between SFGC and iron dextran, and the rare-
ness of the events (0.08%). The single patient with ations [4, 7]. In contrast, at least 31 deaths apparently due
to hypersensitivity reactions to iron dextran occurred serious suspected anaphylactoid reaction to SFGC had
an elevated baseline tryptase level that did not increasebetween 1976 and 1996, and deaths also have been ob-
served rarely following iron sucrose injection [4, 11]. further after drug exposure, suggesting the possibility of
increased total mast cell number or leakiness. This pa-Dextrans are known to elicit IgG and IgE antibody-
mediated reactions [12–20]. We hypothesized that SFGC tient also had a history of multiple drug sensitivities,
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including prior anaphylactoid reactions to iron dextran tions reflect pseudoallergy or host idiosyncrasy, and that
SFGC is not a true allergen. Therefore, caution shouldpreparations, which might be expected in a subject with
fragile mast cells. be used when administering SFGC or any drug to pa-
tients with histories of multiple drug allergies.Lastly, we assessed SFGC allergenicity by use of logistic
regression analysis to identify any cross-reactivity between
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